Headlines about Agios Pharmaceuticals (NASDAQ:AGIO) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.5641437572939 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- David P. Schenkein Sells 13,000 Shares of Agios Pharmaceuticals (AGIO) Stock (americanbankingnews.com)
- Agios Pharmaceuticals (AGIO) Rating Increased to Buy at ValuEngine (americanbankingnews.com)
- Analysts’ Ratings for Athenex and Its Peers in March (finance.yahoo.com)
- Agios Pharmaceuticals (AGIO) Given New $66.00 Price Target at Credit Suisse Group (americanbankingnews.com)
- ValuEngine Upgrades Agios Pharmaceuticals (AGIO) to “Hold” (americanbankingnews.com)
Several research firms recently commented on AGIO. Oppenheimer cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research note on Tuesday, January 16th. Canaccord Genuity set a $90.00 target price on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 12th. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, BidaskClub upgraded shares of Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 3rd. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $85.50.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The business had revenue of $9.80 million during the quarter, compared to analyst estimates of $12.65 million. During the same quarter in the prior year, the company posted ($1.34) EPS. The company’s quarterly revenue was down 56.7% compared to the same quarter last year. research analysts forecast that Agios Pharmaceuticals will post -6.25 EPS for the current year.
In other news, insider Christopher Bowden sold 2,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.75, for a total value of $157,500.00. Following the sale, the insider now owns 2,881 shares of the company’s stock, valued at approximately $226,878.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David P. Schenkein sold 13,000 shares of the company’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $77.72, for a total transaction of $1,010,360.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 213,030 shares of company stock worth $16,499,598. 5.43% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price” was published by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/04/06/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-agios-pharmaceuticals-agio-share-price/2034857.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.